Published in Science on June 18, 1999
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A (2002) 8.10
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 5.94
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol (2009) 5.55
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 4.71
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia (2001) 4.22
Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A (2004) 4.06
Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 3.98
Real-time imaging reveals the single steps of brain metastasis formation. Nat Med (2009) 3.95
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain (2010) 3.53
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med (2001) 3.25
Vasculogenic mimicry and tumor angiogenesis. Am J Pathol (2000) 3.19
Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest (2000) 3.03
The role of prolactin in mammary carcinoma. Endocr Rev (2003) 2.95
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A (2001) 2.81
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol (2005) 2.74
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A (2002) 2.45
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol (2009) 2.41
A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A (2002) 2.35
Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev (2004) 2.32
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol (2009) 2.29
Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A (2002) 2.15
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol (1999) 2.11
Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J (2000) 2.09
Nonlinear modelling of cancer: bridging the gap between cells and tumours. Nonlinearity (2010) 2.08
Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci U S A (2006) 2.03
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer (2002) 2.03
Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest (2000) 2.01
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol (2007) 1.99
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A (2006) 1.96
The vascular basement membrane as "soil" in brain metastasis. PLoS One (2009) 1.95
Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev (2010) 1.92
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol (2011) 1.92
Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res (2010) 1.90
Endothelial cell heterogeneity. Cold Spring Harb Perspect Med (2012) 1.88
The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One (2010) 1.86
Computer simulation of glioma growth and morphology. Neuroimage (2007) 1.83
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A (2003) 1.82
Anticancer strategies involving the vasculature. Nat Rev Clin Oncol (2009) 1.82
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer (2009) 1.80
Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res (2010) 1.79
Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest (2002) 1.78
VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol (2008) 1.77
Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev (2007) 1.76
Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol (2004) 1.71
Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature (2010) 1.70
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res (2011) 1.69
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst (2013) 1.69
Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol (2000) 1.68
Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol (2002) 1.68
B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. Am J Pathol (2003) 1.68
Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. Am J Pathol (2001) 1.67
Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci U S A (2005) 1.65
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res (2011) 1.64
Biology of angiogenesis and invasion in glioma. Neurotherapeutics (2009) 1.61
The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. Cell Rep (2013) 1.61
Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. Circ Res (2013) 1.61
Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol (2006) 1.61
Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res (2009) 1.58
Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? Am J Pathol (1999) 1.54
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer (2010) 1.54
Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia (2009) 1.52
Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. Dev Biol (2008) 1.52
Heterogeneity of the tumor vasculature. Semin Thromb Hemost (2010) 1.48
Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst (2012) 1.47
Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.45
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med (2010) 1.41
Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol (2002) 1.40
Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol (2001) 1.40
Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol (2003) 1.39
Mechanisms of glioma-associated neovascularization. Am J Pathol (2012) 1.39
Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol (2000) 1.38
Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesis. J Theor Biol (2010) 1.37
Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med (2013) 1.36
Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat. Am J Pathol (2000) 1.36
Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol (2002) 1.35
Disruption of Ang-1/Tie-2 signaling contributes to the impaired myocardial vascular maturation and angiogenesis in type II diabetic mice. Arterioscler Thromb Vasc Biol (2008) 1.34
Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia (2009) 1.33
Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol (2007) 1.32
Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci U S A (2003) 1.32
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) (2013) 1.31
Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumors. BMC Cancer (2004) 1.31
Ang-1 gene therapy inhibits hypoxia-inducible factor-1alpha (HIF-1alpha)-prolyl-4-hydroxylase-2, stabilizes HIF-1alpha expression, and normalizes immature vasculature in db/db mice. Diabetes (2008) 1.30
Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep (2009) 1.29
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol (2011) 1.29
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther (2008) 1.28
FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proc Natl Acad Sci U S A (2008) 1.27
Angiogenic sprouting into neural tissue requires Gpr124, an orphan G protein-coupled receptor. Proc Natl Acad Sci U S A (2011) 1.26
The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. J Theor Biol (2012) 1.25
Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol (2009) 1.24
Expression and function of angiopoietin-1 in breast cancer. Br J Cancer (2000) 1.24
Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia (2014) 1.23
Angiogenesis as a therapeutic target in malignant gliomas. Oncologist (2009) 1.23
Breast tumour angiogenesis. Breast Cancer Res (2007) 1.22
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 15.48
Vascular-specific growth factors and blood vessel formation. Nature (2000) 14.42
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 13.95
Identification of ubiquitin ligases required for skeletal muscle atrophy. Science (2001) 12.98
Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol (2001) 10.85
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell (1991) 9.54
Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell (1996) 9.10
Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science (1999) 6.96
Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol (2001) 6.71
Ordered rearrangement of immunoglobulin heavy chain variable region segments. EMBO J (1984) 6.67
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature (1999) 6.50
Developmentally controlled and tissue-specific expression of unrearranged VH gene segments. Cell (1985) 6.21
Preferential utilization of the most JH-proximal VH gene segments in pre-B-cell lines. Nature (1984) 5.75
Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med (2000) 5.58
Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science (1995) 4.90
An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science (1990) 4.63
Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A (2007) 4.27
Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science (1997) 4.26
Development of the primary antibody repertoire. Science (1987) 4.19
Insertion of N regions into heavy-chain genes is correlated with expression of terminal deoxytransferase in B cells. Nature (1984) 4.18
Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron (1996) 4.12
Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science (1999) 4.10
Regulation of the assembly and expression of variable-region genes. Annu Rev Immunol (1986) 4.09
Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature (1997) 4.01
The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell (1996) 3.81
Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res (1998) 3.79
Recombination between immunoglobulin variable region gene segments is enhanced by transcription. Nature (1987) 3.74
Increased vascularization in mice overexpressing angiopoietin-1. Science (1998) 3.67
Regulation of genome rearrangement events during lymphocyte differentiation. Immunol Rev (1986) 3.65
Differential expression of myc family genes during murine development. Nature (1986) 3.57
Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science (1994) 3.53
Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides (1986) 3.51
Introduced T cell receptor variable region gene segments recombine in pre-B cells: evidence that B and T cells use a common recombinase. Cell (1986) 3.51
New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene (1999) 3.45
Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev (1999) 3.35
Microtubule-associated protein 2 kinases, ERK1 and ERK2, undergo autophosphorylation on both tyrosine and threonine residues: implications for their mechanism of activation. Proc Natl Acad Sci U S A (1991) 3.31
Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci (2001) 3.23
NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron (1990) 3.12
PDZ proteins bind, cluster, and synaptically colocalize with Eph receptors and their ephrin ligands. Neuron (1998) 3.09
VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci (2001) 3.08
LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science (1993) 2.93
Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science (1990) 2.91
An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cell (1997) 2.89
Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. Nature (1996) 2.81
Agrin acts via a MuSK receptor complex. Cell (1996) 2.81
Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc Natl Acad Sci U S A (1992) 2.78
A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature (1995) 2.75
The scid defect affects the final step of the immunoglobulin VDJ recombinase mechanism. Cell (1988) 2.71
BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature (1991) 2.70
Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav (1997) 2.67
Secondary genomic rearrangement events in pre-B cells: VHDJH replacement by a LINE-1 sequence and directed class switching. EMBO J (1986) 2.62
Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity (1998) 2.46
Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol (2001) 2.46
Disruption of Eph/ephrin signaling affects migration and proliferation in the adult subventricular zone. Nat Neurosci (2000) 2.45
The alphas, betas, and kinases of cytokine receptor complexes. Cell (1993) 2.45
The receptor for ciliary neurotrophic factor. Science (1991) 2.39
Structure and expression of the murine N-myc gene. Proc Natl Acad Sci U S A (1986) 2.36
N-myc can cooperate with ras to transform normal cells in culture. Proc Natl Acad Sci U S A (1985) 2.33
The human myc gene family: structure and activity of L-myc and an L-myc pseudogene. Genes Dev (1987) 2.33
Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest (1999) 2.32
Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth. Cell (1995) 2.26
Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology (1999) 2.26
Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol (1998) 2.18
Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery (1994) 2.13
Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem (1998) 2.12
Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem (2001) 2.11
The neurotrophins BDNF, NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons. Neuron (1992) 2.11
Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J (1997) 2.09
Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron (1993) 2.01
Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res (2001) 1.95
Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A (1998) 1.93
Biased expression of JH-proximal VH genes occurs in the newly generated repertoire of neonatal and adult mice. J Exp Med (1990) 1.91
Neurotrophic factors: from molecule to man. Trends Neurosci (1994) 1.88
Isolation of scid pre-B cells that rearrange kappa light chain genes: formation of normal signal and abnormal coding joins. EMBO J (1989) 1.86
Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci U S A (1999) 1.84
Ephrin-B3 is the midline barrier that prevents corticospinal tract axons from recrossing, allowing for unilateral motor control. Genes Dev (2001) 1.83
Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci U S A (2001) 1.79
Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat Genet (2000) 1.77
Interactions of Eph-related receptors and ligands confer rostrocaudal pattern to trunk neural crest migration. Curr Biol (1997) 1.77
Neuronal deficits, not involving motor neurons, in mice lacking BDNF and/or NT4. Nature (1995) 1.75
BDNF and NT-4/5 prevent atrophy of rat rubrospinal neurons after cervical axotomy, stimulate GAP-43 and Talpha1-tubulin mRNA expression, and promote axonal regeneration. J Neurosci (1997) 1.71